文献速递细菌感染、耐药与抗菌药物医院感染防控

加拿大医院革兰阳性病原菌17年耐药监测:CANWARD研究(2007-23)

Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23).
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

CANWARD是加拿大抗菌药物耐药联盟与加拿大卫生部合作建立的全国监测研究,每年评估加拿大医院患者分离细菌的抗菌药物敏感性。最常见为金黄色葡萄球菌(20.9%,其中MSSA 16.5%、MRSA 4.4%)、肺炎链球菌(5.2%)和肠球菌属(5.0%);MRSA率在2007-15年从26.0%显著降至19.3%(P<0.0001),随后2016-23年显著回升(16.9%-24.1%,P=0.002)。

要点

  • MRSA率2007-15年从26.0%降至19.3%,2016-23年回升至24.1%
  • MRSA对头孢比罗、利奈唑胺、万古霉素、达托霉素敏感率≥99.9%
  • VRE对达托霉素敏感率98.4%,对利奈唑胺为86.0%

核心结论

  • CANWARD研究提供了17年加拿大医院革兰阳性病原菌的参考药敏监测数据。
  • MRSA率在2007-15年显著下降后,于2016-23年显著回升。

研究设计与样本

  • CANWARD为加拿大抗菌药物耐药联盟与加拿大卫生部合作建立的全国监测研究,2007年成立,每年评估加拿大医院患者分离细菌的药敏。

主要发现

  • 测试菌株来源标本:血液47.9%、呼吸道30.2%、尿液5.7%、伤口16.2%。
  • 菌株来源病房:内科29.9%、急诊24.8%、ICU 19.0%、医院门诊18.1%、外科8.2%。
  • 患者人口学:男性58.9%、女性41.1%;≤17岁13.5%、18-64岁48.5%、≥65岁38.0%。
  • 最常见病原:金黄色葡萄球菌20.9%(MSSA 16.5%/MRSA 4.4%)、肺炎链球菌5.2%、肠球菌属5.0%。
  • MRSA率2007-15年从26.0%降至19.3%(P<0.0001),2016-23年从16.9%升至24.1%(P=0.002);VRE率范围3.8%-18.4%,年际波动明显。

关键数值与推荐

  • MRSA敏感率:头孢比罗100%、利奈唑胺99.9%、万古霉素99.9%、达托霉素99.9%、达巴万星99.8%、泰地唑胺99.4%。
  • VRE敏感率:达托霉素98.4%、利奈唑胺86.0%。

临床怎么用

  • 监测数据显示MRSA率近年回升,经验性抗MRSA治疗需结合本地耐药监测数据。
  • MRSA对利奈唑胺、万古霉素、达托霉素、头孢比罗等敏感率高,VRE对达托霉素敏感率高于利奈唑胺。

局限性

  • 本文聚焦革兰阳性病原菌,未涵盖革兰阴性病原菌的药敏数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: CANWARD is a Canadian Antimicrobial Resistance Alliance (CARA)/Health Canada partnered national surveillance study established in 2007 to annually assess antimicrobial susceptibilities for bacterial pathogens isolated from patients receiving care in Canadian hospitals. This paper focuses on Gram-positive pathogens. METHODS: In total, 25 897 Gram-positive pathogens were received and 22 132 underwent CLSI broth microdilution testing providing susceptibility data. RESULTS: 47.9%, 30.2%, 5.7% and 16.2% of isolates tested were from blood, respiratory, urine and wound specimens, respectively; 29.9%, 24.8%, 19.0%, 18.1% and 8.2% of isolates were from patients in medical wards, emergency rooms, intensive care units, hospital clinics and surgical wards. Patient demographics associated with the isolates were: 58.9% male/41.1% female; 13.5% patients aged ≤17 years, 48.5% 18-64 years and 38.0% ≥ 65 years. Of the 25 897 pathogens received, the most common were: Staphylococcus aureus [20.9% (MSSA 16.5%/MRSA 4.4%)], Streptococcus pneumoniae (5.2%) and Enterococcus spp. (Enterococcus faecalis and Enterococcus faecium) (5.0%). MRSA rates (MRSA as a % of all S. aureus tested) decreased significantly during 2007-15 from 26.0% to 19.3% (P < 0.0001); subsequently they increased significantly through study years 2016-23 (16.9%-24.1%; P = 0.002). VRE rates (VRE as a % of all E. faecium tested) ranged from 3.8% to 18.4%, with marked fluctuation year-to-year. Susceptibility rates for MRSA were highest with: 100% ceftobiprole, 99.9% linezolid, vancomycin and daptomycin, 99.8% dalbavancin and 99.4% tedizolid, while susceptibility rates for VRE were 98.4% daptomycin and 86.0% with linezolid. CONCLUSIONS: The CANWARD surveillance study has provided 17 years of reference antimicrobial susceptibility testing data on Gram-positive pathogens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Zhanel GG, Baxter MR, Golden AR, et al. Gram-positive pathogens from Canadian hospitals: 17 years of results from the CANWARD study (2007-23). J Antimicrob Chemother. 2025. PMID: 40873025. doi:10.1093/jac/dkaf263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。